IMV Appoints Joanne Schindler, M.D., D.V.M. as Chief Medical Officer
“We are very excited to welcome Dr.
Mr. Ors continued, “We also want to take this opportunity to thank Dr.
Dr. Schindler brings over 15 years of experience in the biopharmaceutical industry, primarily in early-stage oncology drug development. Most recently, she served as Vice President, Clinical Development and Executive Medical Director at H3 Biomedicine, overseeing the company’s clinical development efforts. Previously, she worked as Vice President, Clinical Development at
“I am delighted to join IMV at this critical stage in the company’s growth,” said Dr. Schindler. “Immunotherapy is at the forefront of novel treatments for cancer and I have been deeply impressed with IMV’s sophisticated science and data produced to date. Targeted T-cells born out of IMV’s DPX platform have exhibited the potential to elicit a more rapid, robust and sustained immune response over other therapies, particularly when paired with a highly prevalent tumor-associated target like survivin. I look forward to working with the team to advance its clinical portfolio, to unlock the promise of this technology and to bring these important benefits to cancer patients in need.”
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the
Marc Jasmin, Senior Director, Investor Relations, IMV
O: (902) 492-1819, ext: 1042
M: (514) 617-9481
Josh Rappaport, Director, Stern IR
O: (212) 362-1200
Mrs. Delphine Davan, Director of Communications, IMV
M: (514) 968-1046